120 related articles for article (PubMed ID: 409419)
1. [Experimental and clinical study on the dopaminergic receptor stimulating agents (author's transl)].
Ohmoto T; Miyamoto T; Baba Y
No To Shinkei; 1977 Jul; 29(7):?31-40. PubMed ID: 409419
[No Abstract] [Full Text] [Related]
2. [Cerebral dopaminergic mechanisms. Present status of the problem].
Oules MJ; Boscredon J
Ann Med Psychol (Paris); 1979 Nov; 137(9):925-9. PubMed ID: 232829
[No Abstract] [Full Text] [Related]
3. [Piribedil, dopaminergic agonist. Prolonged clinical and electrophysiological study in 60 parkinsonian patients (author's transl)].
Truelle JL; Chanelet J; Bastard J; Six P; Emile J
Nouv Presse Med; 1977 Oct; 6(33):2987-90. PubMed ID: 22844
[TBL] [Abstract][Full Text] [Related]
4. [Acute hypotensive effect of a central dopaminergic agonist, piribedil, administered intravenously in the normotensive human].
Ziegler M; Georgiadis G; Elghozi JL
Arch Mal Coeur Vaiss; 1984 Oct; 77(11):1186-90. PubMed ID: 6441537
[TBL] [Abstract][Full Text] [Related]
5. [Piribedil in the treatment of Parkinson disease (author's transl)].
Nardini M; Sciannandrone R; Fieschi C; De Simone G
Riv Patol Nerv Ment; 1975; 96(2):103-10. PubMed ID: 778998
[TBL] [Abstract][Full Text] [Related]
6. Action of piribedil in Parkinson's disease: I.V. test and oral treatment.
Emile J; Chanelet J; Truelle JL; Bastard J
Adv Neurol; 1975; 9():409-13. PubMed ID: 1096577
[No Abstract] [Full Text] [Related]
7. [New therapeutic indications for a dopamine antagonist, Piribedyl].
Schmitt H; Laubie M; Poignant JC; Krikorian A; Evrard Y; Freyria JL; Arnaud F
Sem Hop; 1978 Mar; 54(5-8):325-34. PubMed ID: 211628
[TBL] [Abstract][Full Text] [Related]
8. Indications of piribedil in L-DOPA-treated parkinsonian patients: physiopathologic implications.
Rondot P; Bathien N; Dumas JL
Adv Neurol; 1975; 9():373-81. PubMed ID: 1096574
[No Abstract] [Full Text] [Related]
9. [Dopamine agonists in the therapy of parkinson syndrome].
Kapfhammer HP; Rüther E
Nervenarzt; 1985 Feb; 56(2):69-81. PubMed ID: 3982566
[No Abstract] [Full Text] [Related]
10. Dopamine receptor stimulating agonists in the treatment of Parkinson's disease.
Agid Y; Barroche G; Bonnet AM; Javoy-Agid F; Kato G; Lhermitte F; Pollak P; Signoret JL
Biomedicine; 1979 Jun; 30(2):67-71. PubMed ID: 383169
[TBL] [Abstract][Full Text] [Related]
11. [Considerations in the drug treatment of parkinsonism (author's transl)].
Hungerbühler JP; Regli F
Schweiz Rundsch Med Prax; 1978 Nov; 67(45):1648-57. PubMed ID: 30976
[No Abstract] [Full Text] [Related]
12. [Drugs and indications for medical treatment in Parkinson's disease (author's transl)].
Allain H; Van den Driessche J; Menault F; Pape D; Reymann JM; Bentue-Ferrer D
Sem Hop; 1980 Feb 8-15; 56(5-6):277-82. PubMed ID: 6243802
[TBL] [Abstract][Full Text] [Related]
13. Presynaptic neuron and postsynaptic dopamine receptor function in long term treatment of Parkinson's disease: a neuroendocrine study.
Agnoli A; Ruggieri S; Baldassarre M; Rocco A; Del Roscio S; D'Urso R; Mearelli S; Falaschi P; Frajese G
Prog Clin Biol Res; 1980; 39():215-24. PubMed ID: 6773067
[No Abstract] [Full Text] [Related]
14. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
Rinne UK; Sonninen V; Marttila R
Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
[TBL] [Abstract][Full Text] [Related]
15. Brain dopamine receptor stimulation and the relief of Parkinsonism: relationship between bromocriptine and levodopa.
Rinne UK; Marttila R
Ann Neurol; 1978 Sep; 4(3):263-7. PubMed ID: 718139
[TBL] [Abstract][Full Text] [Related]
16. Studies on piribedil in Parkinsonism.
Lieberman AN; Shopsin B; Brun YL; Boal D; Zolfaghari M
Adv Neurol; 1975; 9():399-407. PubMed ID: 125032
[No Abstract] [Full Text] [Related]
17. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)].
Ringwald E; Hirt D; Markstein R; Vigouret JM
Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089
[No Abstract] [Full Text] [Related]
18. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
19. Bromocriptine:dopamine-receptor agonist.
Dipalma JR
Am Fam Physician; 1976 Dec; 14(6):88-9. PubMed ID: 1036662
[No Abstract] [Full Text] [Related]
20. Influence of the dopaminergic agonists bromocriptine, piribedil and nomifensine on the sympathetic neural transmission in the nictitating membrane of the cat.
György L; Dóda M
Arch Int Pharmacodyn Ther; 1981 Jan; 249(1):4-11. PubMed ID: 6261705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
